NASDAQ:GNFTGENFIT S A/ADR Stock Price, Forecast & News

$5.40

+0.18 (+3.45 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$5.27

Now: $5.40▼

$5.48

50-Day Range

$5.22

MA: $13.94▼

$22.00

52-Week Range

$5.19

Now: $5.40▼

$24.85

Volume96,500 shs

Average Volume91,428 shs

Market Capitalization$204.30 million

P/E RatioN/A

Dividend YieldN/A

Beta0.74

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Beat the Market (BTM) Rank^™

4.1 Analyst's Opinion

Consensus Rating
GENFIT S A/ADR has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 3 buy ratings, 4 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.75, GENFIT S A/ADR has a potential upside of 913.9% from its current price of $5.40.
Amount of Analyst Coverage
GENFIT S A/ADR has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
GENFIT S A/ADR has received 43 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GENFIT S A/ADR has received 35 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
GENFIT S A/ADR has received 55.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about GENFIT S A/ADR and other stocks. Vote “Outperform” if you believe GNFT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
GENFIT S A/ADR does not currently pay a dividend.
Dividend Growth
GENFIT S A/ADR does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GENFIT S A/ADR insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 2.94% of the stock of GENFIT S A/ADR is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for GENFIT S A/ADR are expected to grow in the coming year, from ($2.18) to ($1.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GENFIT S A/ADR is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GENFIT S A/ADR is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GENFIT S A/ADR has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GNFT

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.genfit.com

Phone33-3-20-16-40-00

Debt

Debt-to-Equity Ratio2.13

Current Ratio6.66

Quick Ratio6.66

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$45.88 million

Price / Sales4.45

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.49 per share

Price / Book2.17

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees148

Outstanding Shares37,833,000

Market Cap$204.30 million

Next Earnings Date8/26/2020 (Estimated)

OptionableNot Optionable

Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

GENFIT S A/ADR (NASDAQ:GNFT) Frequently Asked Questions

How has GENFIT S A/ADR's stock been impacted by COVID-19 (Coronavirus)?

GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNFT stock has decreased by 62.1% and is now trading at $5.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GENFIT S A/ADR?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GENFIT S A/ADR.

When is GENFIT S A/ADR's next earnings date?

GENFIT S A/ADR is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for GENFIT S A/ADR.

What price target have analysts set for GNFT?

9 analysts have issued 12-month price targets for GENFIT S A/ADR's shares. Their forecasts range from $11.00 to $174.00. On average, they expect GENFIT S A/ADR's stock price to reach $54.75 in the next year. This suggests a possible upside of 913.9% from the stock's current price. View analysts' price targets for GENFIT S A/ADR.

Has GENFIT S A/ADR been receiving favorable news coverage?

Press coverage about GNFT stock has been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GENFIT S A/ADR earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutGENFIT S A/ADR.

Who are some of GENFIT S A/ADR's key competitors?

Some companies that are related to GENFIT S A/ADR include Cellectis (CLLS), Avrobio (AVRO), AVITA MED LTD/S (RCEL), Agenus (AGEN), BioCryst Pharmaceuticals (BCRX), Replimune Group (REPL), Aerie Pharmaceuticals (AERI), Aptose Biosciences (APTO), Nantkwest (NK), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), Atara Biotherapeutics (ATRA), Oyster Point Pharma (OYST) and Prevail Therapeutics (PRVL). View all competitors.

What other stocks do shareholders of GENFIT S A/ADR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GENFIT S A/ADR investors own include Intercept Pharmaceuticals (ICPT), InterDigital Wireless (IDCC), Stag Industrial (STAG), Amarin (AMRN), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Vaxart (VXRT), Agile Therapeutics (AGRX), Aimmune Therapeutics (AIMT) and Advanced Micro Devices (AMD).

Who are GENFIT S A/ADR's key executives?

GENFIT S A/ADR's management team includes the following people:

Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
Dr. Dean W. Hum, Chief Operating Officer (Age 57)
Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)

When did GENFIT S A/ADR IPO?

(GNFT) raised $132 million in an initial public offering on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is GENFIT S A/ADR's stock symbol?

GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."

Who are GENFIT S A/ADR's major shareholders?

GENFIT S A/ADR's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.64%), Aperio Group LLC (0.06%) and Morgan Stanley (0.03%).

Which institutional investors are selling GENFIT S A/ADR stock?

GNFT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..

Which institutional investors are buying GENFIT S A/ADR stock?

GNFT stock was purchased by a variety of institutional investors in the last quarter, including Aperio Group LLC, and Morgan Stanley.

How do I buy shares of GENFIT S A/ADR?

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GENFIT S A/ADR's stock price today?

One share of GNFT stock can currently be purchased for approximately $5.40.

How big of a company is GENFIT S A/ADR?

GENFIT S A/ADR has a market capitalization of $204.30 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. GENFIT S A/ADR employs 148 workers across the globe.

What is GENFIT S A/ADR's official website?

The official website for GENFIT S A/ADR is www.genfit.com.

How can I contact GENFIT S A/ADR?

GENFIT S A/ADR's mailing address is PARC EURASANTE 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff